| 000 | 01827 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518091908.0 | ||
| 264 | 0 | _c20200615 | |
| 008 | 202006s 0 0 eng d | ||
| 022 | _a1995-9133 | ||
| 024 | 7 |
_a10.1016/j.jmii.2020.02.012 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLai, Chih-Cheng | |
| 245 | 0 | 0 |
_aAsymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. _h[electronic resource] |
| 260 |
_bJournal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi _cJun 2020 |
||
| 300 |
_a404-412 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAdenosine Monophosphate _xanalogs & derivatives |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAlanine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aAsymptomatic Infections _xepidemiology |
| 650 | 0 | 4 | _aBetacoronavirus |
| 650 | 0 | 4 | _aCOVID-19 |
| 650 | 0 | 4 |
_aChina _xepidemiology |
| 650 | 0 | 4 |
_aChloroquine _xtherapeutic use |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 |
_aCoronavirus Infections _xepidemiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfection Control _xmethods |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPandemics _xprevention & control |
| 650 | 0 | 4 |
_aPneumonia, Viral _xepidemiology |
| 650 | 0 | 4 | _aSARS-CoV-2 |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aLiu, Yen Hung | |
| 700 | 1 | _aWang, Cheng-Yi | |
| 700 | 1 | _aWang, Ya-Hui | |
| 700 | 1 | _aHsueh, Shun-Chung | |
| 700 | 1 | _aYen, Muh-Yen | |
| 700 | 1 | _aKo, Wen-Chien | |
| 700 | 1 | _aHsueh, Po-Ren | |
| 773 | 0 |
_tJournal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi _gvol. 53 _gno. 3 _gp. 404-412 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jmii.2020.02.012 _zAvailable from publisher's website |
| 999 |
_c30743394 _d30743394 |
||